{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:21:51Z","timestamp":1791832911145,"version":"4.3.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010124","name":"Erich und Gertrud Roggenbuck-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010138","name":"Fritz-Bender-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010138","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Non-small cell lung cancer (NSCLC) is currently the leading cause of cancer-related death worldwide, and the incidence of brain metastases (BM) in NSCLC patients is continuously increasing. The recent improvements of systemic treatment in NSCLC necessitate continuous updates on prognostic subgroups and factors determining overall survival (OS). In order to improve clinical decision-making in tumor boards, we investigated the clinical determinants affecting survival in patients with resectable NSCLC BM. A retrospective analysis was conducted of NSCLC patients with surgically resectable BM treated in our institution between 01\/2015 and 12\/2020. The relevant clinical factors affecting survival identified by univariate analysis were included in a multivariate logistic regression model. Overall, 264 patients were identified, with a mean age of 62.39 \u00b1 9.98 years at the initial diagnosis of NSCLC BM and OS of 23.22 \u00b1 1.71 months. The factors that significantly affected OS from the time of primary tumor diagnosis included the systemic metastatic load (median: 28.40 \u00b1 4.82 vs. 40.93 \u00b1 11.18 months, p = 0.021) as well as a number of BM &amp;lt;2 (median: 17.20 \u00b1 2.52 vs. 32.53 \u00b1 3.35 months, p = 0.014). When adjusted for survival time after neurosurgical intervention, a significant survival benefit was found in patients &amp;lt;60 years (median 16.13 \u00b1 3.85 vs. 9.20 \u00b1 1.39 months, p = 0.011) and, among others, patients without any concurrent systemic metastases at time of NSCLC BM diagnosis. Our data shows that the number of BM (singular\/solitary), the Karnofsky Performance Status, gender, and age but not localization (infra-\/supratentorial), mass-edema index or time to BM occurrence impact OS, and postsurgical survival in NSCLC BM patients. Additionally, our study shows that patients in prognostically favorable clinical subgroups an OS, which differs significantly from current statements in literature. The described clinically relevant factors may improve the understanding of the risks and the course of this disease and Faid future clinical decision making in tumor boards.<\/jats:p>","DOI":"10.3389\/fonc.2022.951805","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:26:54Z","timestamp":1666261614000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical determinants impacting overall survival of patients with operable brain metastases from non-small cell lung cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Andras","family":"Piffko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Asey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka","family":"Ristow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Salamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Wikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile L.","family":"Maire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Lamszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sauvigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Mohme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013Small-Cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-Expressing, locally advanced or metastatic non-Small-Cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30801-0","article-title":"Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-Small-Cell lung cancer (KEYNOTE-189): A multicentre, double-blind, randomised, placebo-controlled","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non\u2013small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020593","article-title":"Treatment of brain metastases of non-small cell lung carcinoma","volume":"22","author":"Rybarczyk-Kasiuchnicz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32714","article-title":"Current multidisciplinary management of brain metastases","volume":"126","author":"Moravan","year":"2020","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuchi.2021.04.001","article-title":"Brain metastases: An update on the multi-disciplinary approach of clinical management","volume":"68","author":"Mitchell","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13071616","article-title":"The management of brain metastases\u2013systematic review of neurosurgical aspects","volume":"13","author":"Proescholdt","year":"2021","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cllc.2017.10.003","article-title":"Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings","volume":"19","author":"Walker","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12123618","article-title":"Timing of development of symptomatic brain metastases from non-small cell lung cancer: Impact on symptoms, treatment, and survival in the era of molecular treatments","volume":"12","author":"J\u00fcnger","year":"2020","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-30-10","article-title":"Brain metastases from solid tumors: Disease outcome according to type of treatment and therapeutic resources of the treating center","volume":"30","author":"Fabi","year":"2011","journal-title":"J Exp Clin Cancer Res"},{"key":"B14","volume-title":"Bericht zum Krebsgeschehen in Deutschland 2016","author":"Barnes","year":"2016"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-019-03149-4","article-title":"Natural history, clinical course and predictors of interval time from initial diagnosis to development of subsequent NSCLC brain metastases","volume":"143","author":"Smith","year":"2013","journal-title":"J Neuro-Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/J.PRRO.2011.12.004","article-title":"Radiotherapeutic and surgical management for newly diagnosed brain Metastasis(Es): An American society for radiation oncology evidence-based guideline","volume":"2","author":"Tsao","year":"2012","journal-title":"Pract Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases","volume":"17","author":"Suh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study.\u201d","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071562","article-title":"Correlation of clinical parameters with intracranial outcome in non-small cell lung cancer patients with brain metastases treated with pd-1\/Pd-L1 inhibitors as monotherapy","volume":"13","author":"Rounis","year":"2021","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Weichselbaum","year":"1995","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00847","article-title":"The 46th David a. karnofsky memorial award lecture: Oligometastasis \u2014 from conception to treatment","volume":"36","author":"Weichselbaum","year":"2018","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04278-6","article-title":"Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis","volume":"9","author":"Pitroda","year":"2018","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-012-9542-9","article-title":"Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases","volume":"30","author":"Spanberger","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1057388","article-title":"Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases","volume":"5","author":"Berghoff","year":"2016","journal-title":"OncoImmunology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.951805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T10:27:02Z","timestamp":1666261622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.951805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":25,"alternative-id":["10.3389\/fonc.2022.951805"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.951805","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"951805"}}